IL-15 to enhance the effectiveness of GPC3-targeting CAR T cells in solid tumors
Yan Leyfman shared on LinkedIn:
“Study from Baylor College of Medicine showed that IL-15 enhances the effectiveness of GPC3-targeting CAR T cells in solid tumors by boosting their expansion, survival, and antitumor activity. In a clinical study, IL-15 co-expression increased response rates to 33% and disease control to 66%, though it also raised cytokine release syndrome risk, which was manageable. Tumor-infiltrating CAR T cells in responders showed beneficial epigenetic and immune activation changes, highlighting IL-15’s potential to improve CAR T cell therapies for solid cancers.”
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers | Nature
Authors: David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N. Courtney, Azlann B. Arnett, Julien Fleurence, Ramy Sweidan, Tao Wang, Huimin Zhang, Prakash Masand, John M. Maris, Daniel Martinez, Jennifer Pogoriler, Navin Varadarajan, Sachin G. Thakkar, Deborah Lyon, Natalia Lapteva, Mei Zhuyong, Kalyani Patel, Dolores Lopez-Terrada, Carlos A. Ramos, Premal Lulla, Tannaz Armaghany, Bambi J. Grilley, Stephen Gottschalk, Gianpietro Dotti, Leonid S. Metelitsa, Helen E. Heslop, Malcolm K. Brenner, Pavel Sumazin and Andras Heczey
Yan Leyfman MD, is the Co-founder and executive director of MedNews Week. He is also the medical correspondent at OncLive. He is also the Executive Committee Member at Music Beats Cancer. He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023